Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer - a Danish register-based study from 2005 to 2016

Keyphrases

• Register Study 100%
• Danish Registers 100%
• HER2-positive Breast Cancer 100%
• Metastatic Breast Cancer 100%
• HER2-positive 100%
• Cost of Illness 100%
• Direct Costs 80%
• Trastuzumab 60%
• Indirect Costs 60%
• Breast Cancer Recurrence 60%
• Breast Cancer Patients 40%
• Cancer Register 40%
• Metastasis 40%
• Patient Register 40%
• Breast Cancer Diagnosis 40%
• Labor Productivity 40%
• Primary Care 20%
• Breast Cancer 20%
• Medicinal Products 20%
• Pathology Database 20%
• Civil Registration System 20%
• First Year 20%
• Early Breast Cancer 20%
• Patient-level Data 20%
• National Health Service 20%
• Municipal Services 20%
• Total Direct Costs 20%
• Labor Costs 20%
• HER2-positive Early-stage Breast Cancer 20%
• Database Education 20%
• Population Education 20%

Medicine and Dentistry

• Health Care Cost 100%
• Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 100%
• Cost of Illness 100%
• Breast Cancer 85%
• Recurrent Disease 71%
• Metastatic Carcinoma 42%
• Trastuzumab 42%
• Cancer Registry 28%
• Population Research 28%
• Cancer Diagnosis 28%
• Metastatic Breast Cancer 28%
• Primary Health Care 14%
• Identified Patient 14%
• National Health Service 14%

Biochemistry, Genetics and Molecular Biology

• Trastuzumab 100%
• Population Research 66%